Clinical Research Directory
Browse clinical research sites, groups, and studies.
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Sponsor: COMPASS Pathways
Summary
The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.
Official title: A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2026-09
Completion Date
2029-09
Last Updated
2026-09-04
Healthy Volunteers
No
Conditions
Interventions
COMP360 psilocybin
COMP360 psilocybin administered with monitoring and support
Locations (2)
Florida
Orlando, Florida, United States
NY
New York, New York, United States